Biotech company Kardigan closed its US initial public offering Wednesday, raising $400 million after selling more shares than originally planned and pricing them at the highest end of the marketed range. The strong debut signals a rebound in investor appetite for biotech stocks after a sluggish stretch for the sector.
Why the offering was upsized
Kardigan and its underwriters increased the size of the IPO in the days leading up to pricing, a sign that demand from institutional and retail investors exceeded expectations. By pricing at the top of the range, the company maximized its haul from the offering, netting $400 million before expenses. The move reflects confidence in Kardigan's pipeline and broader market conditions.
A bright spot for biotech IPOs
The successful offering stands out in a year when many biotech listings have struggled to gain traction. Several companies in the sector have pulled or downsized their IPOs amid volatile markets and cautious investor sentiment. Kardigan's ability to upsize and price strongly suggests a turning point, at least for well-positioned firms. The company now joins a small group of biotech IPOs this year that have priced above expectations.
What comes next
Kardigan's shares are set to begin trading on the Nasdaq under the ticker symbol KARD. The company will use the proceeds to advance its drug development programs, according to its prospectus. Investors and analysts will watch the stock's first-day performance closely, as it could set the tone for other biotech companies planning to go public in the coming months.
